Displaying all 4 drugs
Durvalumab
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Synonyms: … Durvalumab …
Matched Name: … Durvalumab …
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with ... [L12621,L12627] Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous …
Matched Categories: … durvalumab …
Matched Name: … Durvalumab …
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with ... [L12621,L12627] Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous …
Matched Categories: … durvalumab …
Tremelimumab
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours...
Approved
Investigational
Matched Synonyms: … Tremelimumab …
Matched Name: … Tremelimumab …
Matched Description: … [durvalumab] to treat hepatocellular carcinoma. ... was approved for combined use with [durvalumab]. ... Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against …
Matched Categories: … tremelimumab …
Matched Products: … TREMELIMUMAB ASTRAZENECA ... Tremelimumab Astrazeneca …
Matched Name: … Tremelimumab …
Matched Description: … [durvalumab] to treat hepatocellular carcinoma. ... was approved for combined use with [durvalumab]. ... Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against …
Matched Categories: … tremelimumab …
Matched Products: … TREMELIMUMAB ASTRAZENECA ... Tremelimumab Astrazeneca …
Axatilimab
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
Investigational
Matched Description: … Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF …
Tiragolumab
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
Investigational
Matched Description: … investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab …
Displaying all 4 drugs